 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareMetabolic Complications: Treatment
- FDA Decision on Egrifta (Tesamorelin) Delayed Until Fall: A Blog Entry by Myles Helfand (August 3, 2010)
From The Body - Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir (July 26, 2010)
From National AIDS Treatment Advocacy Project - Raltegravir vs. Efavirenz: Focus on Lipodystrophy, Lipids and Other Changes (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange - A Clinical Overview of Tesamorelin (June 3, 2010)
From AIDSinfo - FDA Committee Unanimously Recommends Egrifta for Lipodystrophy (May 27, 2010)
In POZ Magazine - FDA Staff: Theratech Drug Works, but Risks Weighed (May 26, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Belly Fat Drug Debated Even Before FDA Approval (February 22, 2010)
In Housing Works AIDS Issues Update, from Housing Works - Metabolic Complications of HIV Treatment (December 4, 2007)
Translating HIV research into practice.
From The Body PRO - Rosiglitazone Analysis Sparks Safety Controversy (May 22, 2007)
From aidsmap.com - Treating Morphologic and Metabolic Complications in HIV-Infected Patients on Antiretroviral Therapy (February 2005)
[Archived Article]
Consensus statement from an advisory committee of the International Association of Physicians in AIDS Care.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Abstract 12: A Randomized, Double-Blind, Placebo-Controlled Study of Rosiglitazone for Patients With HIV Lipodystrophy (October 1, 2003)
[Archived Article]
5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 8-11, 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Metabolic Complications: A Look at the IAS Guidelines (Spring 2003)
[Archived Article]
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America - Retrovirus 2003: Management of Metabolic Complications (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The Many Faces of Human Growth Hormone (Winter 2002/2003)
[Archived Article]
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Summary of IAS-USA Recommendations for the Management of Metabolic Complications (November 26, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Ask Dr. Jeff: Surgery to Correct Body-Shape Changes (Fall 2002)
[Archived Article]
Jeffrey T. Schouten, M.D. addresses patient concerns.
To read PDF, click here.
In STEP Perspective, from Seattle Treatment Education Project - Fibrates and Statins and Glitazones (Oh My!) (Spring 2002)
[Archived Article]
A review of lipid- and insulin-lowering drugs in development.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America - God Breast Ye Merry Gentlemen (November/December 2001)
[Archived Article]
Dr. Daniel Berger discusses abnormal enlargement of breast tissue in HIV infection.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.